Navigation Links
Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
Date:3/29/2009

ilatory anaerobic threshold (p=0.03). These effects were largely maintained at twelve months as well.

"This subgroup of the less severely impaired patients appeared to demonstrate an overall greater response rate that those in the control group," noted Dr. Alan Kadish, professor, Division of Cardiology, Feinberg School of Medicine, Northwestern University. "We are particularly encouraged by the findings in this subgroup of patients and look forward to focusing on this subgroup in our next study."

Yuval Mika, chief operating officer of Impulse Dynamics, commented, "The data show that CCM therapy has the potential to be an important new therapy for a greatly underserved group of heart failure patients. We have a clear pathway for further studies of CCM in this population which we believe will have favorable outcomes in the near future."

For a complete copy of the study, please contact Erich Sandoval at 917-497-2867 or esandoval@lazarpartners.com.

About Cardiac Contractility Modulation (CCM) Therapy

Cardiac Contractility Modulation is a new treatment for patients with heart failure. Unlike electrical signals delivered by other cardiac devices, such as pacemakers and implantable defibrillators, CCM signals do not initiate a heartbeat. Rather, CCM signals are intended to modify heart cell function in a manner that improves the strength of the heart muscle, therefore potentially enhancing the heart's overall pumping ability.

About the OPTIMIZER System

The OPTIMIZER System is CE Marked and commercially available in Europe and is currently under clinical investigation at major U.S. research and academic facilities. It consists of a pulse generator and conventional pacing leads which deliver the therapy to
'/>"/>

SOURCE Impulse Dynamics (U.S.A.) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
2. New CoMotion(R) Trials Software by General Dynamics Enables Rapid, Interactive Sharing of Real-time Data for Clinical Trials
3. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
7. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
8. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
9. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
10. Alba Therapeutics Corporation Announces the Next Clinical Trial of Its Lead Compound, Larazotide Acetate and Promotions
11. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Global and Chinese Aseptic Packaging Industry Report is a ... the global Aseptic Packaging industry with a focus on ... overview of the industry including definitions, classifications, applications and ...
(Date:7/30/2014)... PITTSBURGH , July 30, 2014   ... Markets Groups Inc.: OTC Pink: UPZS), a Delaware ... a distribution agreement with Larasan Pharmaceutical Corporation ("Larasan"), a ... products.  According to the agreement, US-based Larasan will ... gourmet 6" frozen pizza through Larasan,s vast distribution ...
(Date:7/30/2014)... and PARIS , July 30, 2014 ... and Sanofi (EURONEXT: SAN and NYSE: SNY ... trials of alirocumab in people with hypercholesterolemia met their ... baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks ... investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type ...
Breaking Medicine Technology:Global and Chinese Aseptic Packaging Industry Report 2014 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 2Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8
... study shows 90-day statin drug claims filled through a mail ... supply from a retail pharmacy. The findings of the study ... management, will be presented at the Academy of Managed Care ... Minn. April 27-29. Waste occurs when patients stop ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, today announced that it will report ... ("4Q FY2010") and the full fiscal year ended March ... June 2, 2011. The Company will also ...
Cached Medicine Technology:For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste 2China Medical Technologies to Announce Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2011 on June 2, 2011 2
(Date:7/30/2014)... Of the many sub-groups of cells jockeying for ... not be those that can proliferate the fastest, researchers ... in an advance online publication of the journal ... the treatment of cancer with precision medicines, the study ... are truly driving the tumor,s growth and metastasis and ...
(Date:7/30/2014)... According to the market research ... by Technology (ICS, MES, ERP, ITS), Field Devices, ... Application (Process, Discrete) - Global Forecast & Analysis ... Mexican market is expected to reach $6.99 Billion ... Browse 70 market data Tables and 96 Figures ...
(Date:7/30/2014)... Everyone knows that the internet is the absolute center of ... for something to buy, trying to reconnect with friends, or ... much always going to be the go to resource. That ... happy to announce the launch of their brand new website ... Whether a person wants to know what the Sierra Dental ...
(Date:7/30/2014)... July 30, 2014 Shabaikai is an ... forests of the Pomo Indians located on the shores ... the river Shabaikai, meaning ‘crooked snake’. Clarkson takes the ... and the violence of prohibition and organized crime, providing ... River. Here, the most powerful men in the world ...
(Date:7/30/2014)... Texas (PRWEB) July 30, 2014 “North ... key market data on the North America Contrast Media ... US dollars, and volume (in units) and average price ...     CT Injectors ,     Interventional Cardiology/Angio Injectors and ... (or contrast agent) is a substance used to enhance ...
Breaking Medicine News(10 mins):Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 2Health News:Target growth-driving cells within tumors, not fastest-proliferating cells 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Sierra Dental Releases New Website For Fort Lauderdale Residents 2Health News:Bill E. Clarkson Releases Debut Fact-Based Novel, Shabaikai 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4
... A study featured in the November issue of the ... simple questionnaire designed to identify patients at high risk of ... cases of cancer of the original 430 patients who qualified ... The study was conducted in primary care physician offices among ...
... ... with a compound that fights chronic liver disease Infections caused by Hepatitis C. Lloyd ... claim is incurable. The Blueberry Extract has a compound derived from blueberry leaves and ... , ...
... ... Targeted immunotherapy has been an attractive new therapeutic area for a ... cells without damaging surrounding normal tissue. New study results demonstrate high ... lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have ...
... ... its camera housings for underwater use, it turned to ZaGO Manufacturing Company for an answer. ... possibility of water leaking into the switch operating the camera. Vision Tech benefited from ... ...
... ... , ... -- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, ... , , , , ,For safety and ease of use, the non-vented Secondary Set offers the ...
... November 2009 issue of the Journal of Thoracic Oncology ... and treatment may be attributed to health care system discrepancies. ... researchers studied the timing of lung cancer diagnosis and treatment ... patient population within two different hospital systems. David E. Gerber, ...
Cached Medicine News:Health News:Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin 2Health News:Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin 3Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 2Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 3Health News:Immunotherapy Demonstrates Long-Term Success in Treating Lymphoma 4Health News:ZaGO Manufacturing Company Seals the Deal -- Underwater 2Health News:Carmel Pharma Introduces PhaSeal Secondary Set (C60) 2
... Medication Delivery., ,Designed for adolescent ... incorporates an additional lumen and injection ... the cuff., ,SHERIDAN offers three ... CO2 monitoring, pressure monitoring or medication ...
... For Laryngotracheal Instillation of Topical Anesthetic, ... populations, this cuffed tube incorporates an ... spray application of topical anesthetic above ... offers three endotracheal tubes designs which ...
... ,Designed for neonatal and pediatric patient ... monitoring lumen within the wall of the ... Luer lock connector bonded to lumen line ... monitoring or syringe irrigation of medication., ...
SPIRAL-FLEX® Oral Precut Reinforced Tubes...
Medicine Products: